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Invasive fungal infections (IFIs) have emerged as a serious threat in imniunocomproniised patients during the 
last two decades. Host defenses including appropriate cytokine responses and intact phagocytic function are 
necessary to combat IFIs. Several cytokines have been investigated and developed for preventive and 
therapeutic use. Among them, granulocyte colony-stimulating factor (G-CSF) has been mostly studled and 
used for various purposes, the most important being the faster recovery from neutropenia 11 1. Other cytokines 
with potential clinical significance in relation to IF1 are granulocyte-macrophage colony-stimulating factor 
(GM-CSF), interferon-y (IFN-y) and macrophage colony-stimulating factor. Supported by a large number of 
preclinical studies but limited clinical results their potential utility against IF1 has been suggested. In this 
review, certain questions related to this issue are discussed based on data already avadable and an attempt to 
consider future research is made. 
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DOES GRANULOCYTE COLONY-STIMULATING FACTOR 
PROVIDE THE IMMUNE SYSTEM WITH ANY HELP AGAINST 
INVASIVE FUNGAL INFECTION? 
This question has been intensively explored with many in vitro 
and animal studies, although limited clinical results exist. The 
in vitro studies have been predonlinantly performed with use of 
human neutrophils (PMNs) and human granulocyte colony- 
stimulating factor (G-CSF) using as targets either Candida 
albicans or Aspergillusfumigatus (Table 1). A few studies have 
used other Candida spp., Trichosporon beigelii or non-dspergilltrs 
filamentous fung. Most ofthese studies have suggested that G- 
CSF, under specific conditions, up-regulates antifungal PMN 
function against the fungi studied. However, there are 
differences in antifungal enhancement related to the time of 
incubation of PMNs and fungi as well as to the growth stage of 
the fungi, i.e. conidial or hyphal form [l I]. 
In addition to the in uitro results, a number of in oivo studies 
of G-CSF administration have been performed using experi- 
mental animals, mostly mice, in preventive, early therapeutic 
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Table 1 In vitro and ex vivo effects of G-CSF on antifungal activity of 
PMNs 
Increase in number of PMNs 
Increase in PMN oxidadive burst in response to C. albicans [2] and 
A. fumigatus [3] 
Increase in PMN-mediated damage of Candida spp. (albicans [4]. 
tropicalls and parapsilosis [5]), A. fumigatus [3], F. solani [6]. 
R. arrhizus [7] 
Restores the reduced anti-Candida and anti-Aspergillus activity of 
PMN from HIV-infected patients [8,9] 
Prevents the corticosteroid-induced suppression of PMN ability to 
damage A. fumigatus hyphae [ lo ]  
Combined with IFN-.I exhibits increased effect on anti-Aspergillus 
activities of PMNs [3] 
or late therapeutic models of invasive fungal infection (IFI) 
(Table 2). These studm have predominantly used either C. 
albicans or A. fumigatus as challenging agents. The intravenous 
route has been used in models of candidiasis and intravenous or 
intratracheal routes in models of aspergillosis. Although there 
are important differences in methodology, goals and outcome 
in these studies, it appears that G-CSF protects neutropenic 
animals from IF1 by faster recovery from neutropenia. G-CSF 
did not protect mice that had been immunosuppressed by 
corticosteroid treatment from either candidiasis or aspergllosis 
[13,19] or profoundly and persistently neutropenic mice 
from candidiasis [12]. G-CSF improved outcome of non- 
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neutropenic mice with invasive canddiasis f12-141 as well as 
of mice with less severe neutropenia with candidiasis and 
aspergdlosis [13-161 (Table 2). 
Table 2 Effect of G-CSF in animal models of IF1 
~ 
Candidiasis 
Protection of non-G mice [12-141 
Protection of G mice [13-161 
No protection of persistently G mice and rabbits [12,17] 
No protection of corticosteroid-treated mice [I 31 
Synergy with fluconazole in both non G and G mice [13,14,18] 
Synergy with amphotericin B or itraconazole in G mice [13,16] 
Aspergillosis 
Protection of non-G mice It91 
Protection of G mice [15,19] 
No protection of corticosteroid-treated mice [I 9.201 
Synergy with itraconazole in corticosteroid-treated mice [I 91 
Synergy with amphotericin B, itraconazole and posaconazole in G 
Antagonism with posaconazole in corticosteroid-treated mice [20] 
Trichosporonosis 
Protection of G mice[21] 
mice /19,20] 
G indicates neutroDenic 
Clinical data that support efficacy of G-CSF are limited. 
Except for a number of case reports showing efficacy of the 
combination of G-CSF and antifungal therapy to control the 
infection (Table 3 ) ,  few randomized studies have examined the 
effect of G-CSF in immunocompronlised patients with 
henntologcal malignancies and in non-neutropenic patients 
as prevention or treatment, respectively (Table 4). Although 
there has been no consistent protection from IF1 found, there 
are several indcations of improvement of IF1 outcome 
includmg decreased need of use of antifungal therapy (Table 4). 
DOES THE COMBINATION OF G-CSF WITH ANTIFUNGAL 
AGENTS WORK BETTER THAN ANTIFUNGAL AGENTS 
ALONE? 
In addition to amphotericin B and its lipid formulations, 
newer azoles and other classes of antifungals possess an 
important role in the management of IFI. The issue of 
potential interaction (either synergism or antagonism) between 
G-CSF and antifungal agents has been studied in witro and in 
murine models. First, in vitro studies have shown synergy of G- 
CSF and the azole voriconazole when added to PMNs against 
A. fumigatus [33]. Antifungal activity was evaluated as 
oxidative burst (chemiluminescence) in response to extracts 
of A. fumigatus and as PMN-mediated kdling of A. fumigatus 
conida. G-CSF and granulocyte-macrophage colony-stimu- 
lating factor (GM-CSF) were found to enhance PMN- 
medated damage of A. fumz'gufus hyphae and voriconazole 
exhbited a synergistic effect with these cytokines. 
Similarly, both G-CSF and GM-CSF enhanced the can&- 
dacidal activity ofPMNs and they increased the collaboration of 
PMNs with voriconazole for lulling. Voriconazole also 
collaborated with GM-CSF-activated monocytes (MNCs) for 
enhanced killing of C. albicans [34]. The same group also 
evaluated the effect of G-CSF and GM-CSF on the 
Table 3 Case reports of patients with IF1 who were treated with combined antifungal therapy and G-CSF 
Ref. No. of 
PtS 
Under ly ing 
cond i t i on  
CG D 
AML and 
AlloBMT 
Neutropenia 
Neutropenia 
ALL 
Neutropenial 
leukemia 
Neutropenia 
AML 
Fungal 
i n fec t i on  
Ant i fungal  
therapy 
invasive multifocal 
infection due to 
A. nidulans 
T. beigelii septicemia 
lnvasive zygomycosis 
Fusariurn oxysporurn 
infection 
I nvasive thoracopulmonary 
mucormycosis 
Rhinocerebral 
mucormycosis 
lnvasive pulmonary 
aspergillosis 
Candidal brain abscesses 
Liposomal arnpho 6; 
G-CSF-elicited PMNs 
Ampho B 
Arnpho B lipid 
complex 
Ampho B + 5FC 
Amphotericin B 
Liposomal ampho B 
Liposomal ampho B 
with S 
(2 PtS) 
Ampho B with S 
Ou tcome 
Cured 
Cured 
Cured 
Cured 
Cured 
Cured 
2 died 
2 R (with S), 1 CR 
(without S) 
Cured (with S )  
R, response; CR. complete response; S. surgery; CGD, chronic granulomatous disease; AML, acute myeloid leukemia; ALL, acute lymphoblastic 
leukemia; allo-BMT. allogeneic bone marrow transplantation. 
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Table 4 Ctinical studies of use of G- 
CSF for prevention or treatment of IFI Ref. UnderlVing condi t ion Outcome 
in cancer patients 
[30] Hematological malignancies More clinical responses, decrease in superinfections, 
and G-related infections 
[31] Acute myeloid leukemia 
hospitalization, antibiotic use, mortality; fungal infections 
only in the group treated with antibiotic alone 
Reduced use of amphotericin B, no difference in incidence 
of infections, fewer fungal infection-related deaths in the 
G-CSF group 
No significant difference in survival, more favorable 
outcome in patients with higher PMN counts due 
to G-CSF 
[32] Non-G patients with 
invasive candidiasis 
G indicates neutropenic. 
candldacidal activity of PMNs and MNCs and the synergy with 
fluconazole. Incubation of phagocytes with G-CSF and GM- 
CSF enhanced the canddacidal activity and fluconazole 
exhibited a synergistic effect with these cytokines [35,36]. 
The in vivo results of combined effects of G-CSF and 
antifungal agents are somewhat more complicated and appear to 
depend on the status of the immune system. In an early study of 
the effects of G-CSF on murine aspergillosis, while G-CSF 
given to corticosteroid-treated mice did not show a s igdcant  
protection from subsequent development of aspergdosis, such a 
protection was demonstrated when simultaneous antifungal 
chemotherapy with itraconazole was administered [19]. By 
comparison, in cyclophosphamide-treated mice, G-CSF was 
reported to offer protection even without simultaneous 
antihngal chemotherapy. Moreover, when prophylactic treat- 
ment with G-CSF was combined with antihngal agents, 
synergy was observed with amphotericin B or itraconazole at 
h g h  dose but not with 5-fluorocytosine. Similarly, the 
combination of G-CSF with antifungal therapy such as 
amphotericin B, fluconazole and itraconazole had a synergistic 
effect in cyclophosphamide-treated mice with candidiasis [13]. 
Synergism has been also shown between G-CSF and 
posaconazole, a recent triazole under development, in 
neutropenic mice with aspergdosis [20]. By comparison, in 
corticosteroid-pretreated mice, G-CSF strongly antagonized 
the antifungal activity of posaconazole. While posaconazole 
reduced fungal counts in lung tissue and prolonged survival, 
the combination therapy with G-CSF reversed this effect. 
These findings suggest that the combination of G-CSF with an 
antifungal agent may be synergstic, indifferent or antagonistic 
depending on not well-understood factors. 
O n  the other hand, the combination of G-CSF with 
fluconazole had a synergistic effect on clearance of C. albicans 
from organs ofinfected nonimmunocompromised mice but not 
on the survival of the animals [18]. In another similar murine 
model, while G-CSF alone waq ineffective, combined with 
fluconazole it was beneficial in acute murine candidiasis, 
whether as prophylaxis or treatment of immunocompetent or 
neutropenic mice. Specifically, the use ofa combined regimen as 
prophylaxis prolonged the survival beyond that for fluconazole 
alone. When used as treatment, but only immediately after 
infection, the combination of G-CSF with fluconazole s i p -  
ficantly reduced kidney tissue counts [14]. Likewise, the survival 
rate was greater in neutropenic mice with candidiasis treated 
with combined amphotericin B and G-CSF than in those treated 
with amphotericin B alone [16). Based on the avadable data, the 
synergstic activity of phagocytes, cytokmes and antifbgal agents 
is an area of active research with potential clinical usefulness. 
A randomized trial of G-CSF administration together with 
fluconazole to non-neutropenic patients with invasive candi- 
diasis was performed recently. Although no significant 
difference in survival was observed in the combination arm 
as compared to fluconazole alone [32], the patients who had 
higher numbers of PMNs caused by G-CSF administration 
had more favorable outcomes than the patients who did not 
increase their PMN counts. 
HOW DOES G-CSF COMPARE WITH OTHER CYTOKINES AS 
ADJUVANT THERAPY AGAINST IFI? 
An important question is which cytokine has better antifungal 
activity. To address this, Gaviria et al. compared the three most 
extensively studied cytokines G-CSF, GM-CSF and IFN-y. 
Specifically, the antifungal activity of PMNs taken from 
healthy donors was evaluated for antifungal activity measured 
as hyphal damage against C. albicans, A.  fumigatus and Fusarium 
solani 161. The study showed that IFN-y exhibited the broadest 
antifungal activity and enhanced hyphal damage of A.  
fumigatus. G-CSF significantly increased PMN-mediated 
damage of F. solani hyphae only. 
In another study, G-CSF, GM-CSF or no cytokine were 
administered to 51 oncology patients and their ex v im 
functional effects on PMNs and MNCs were compared. 
Monocyte-induced kilhng of C. albicans was enhanced in GM- 
CSF-treated patients in the post-period compared with the 
pre-period ( P =  0.06) and in comparison with the post period 
of control patients (P= 0.011) and G-CSF-treated patients 
( P =  0.067). Monocyte function was not affected in G-CSF- 
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treated patients. No differences in PMN function against C. 
albicans were observed between patients receiving either 
cytolune [37]. 
To date, no randomized trial has compared the efficacy of 
cytokines in the same clinical setting. However, in a 
retrospective study of 145 consecutive patients receiving 
high-dose chemotherapy with or without stem cell transplan- 
tation, Peters et al. [38] performed an analysis of the 
relationship between the type of CSF administered and the 
incidence of IFI. There were no statistical differences in 
patient characteristics and risk factors for fungal infections. The 
risk ratio for developing IF1 in patients treated with G-CSF or 
no cytokine was 4.20 times higher (P= 0.023) compared with 
patients who received a monocyte/macrophage-stimulating 
cytokine (GM-CSF, M-CSF or IL-3). Additionally, there was 
a trend towards increased mortahty in patients treated with G- 
CSF or no cytokine, however, the difference was not 
statistically significant. Thus, it may be that GM-CSF has 
some advantages compared to G-CSF against IFI, and 
comparative trials can help determine the optimal utdity of 
specific cytokines in different clinical settings. 
One of the notable advantages of G-CSF compared to other 
cytolunes is the lack of major side-effects as well as its minor 
toxicity profile. Because of its abhty to enhance recovery &om 
neutropenia and activate PMNs as well as due to its lack of 
significant side-effects, it has been administered to healthy 
donors with the purpose that their G-CSF-elicited white blood 
cells are transfused to neutropenic patients with serious IF1 [39]. 
The results reported have been promising. However, the main 
&sadvantage of G-CSF compared to other cytokines is that it 
does not appear to exert sigruficant activity during neutropenia 
except when it is used to elicit PMNs in the donor and these 
PMNs to be transfused to the patient. In profoundly 
neutropenic patients it may be inferior to GM-CSF [37,38] 
presumably because of a lack of activity on monocyte/ 
macrophage system which is less affected during neutropenia. 
ARE THERE IMMUNE SYSTEM STATES IN WHICH G-CSF 
WORKS BETTER? 
Theoretically, G-CSF is able to act only when PMNs are 
present; during neutropenia, only by increasing the number of 
PMNs can it help and, thus, profoundly cytopenic patients 
would be expected to derive little benefit from this therapy. 
This consideration is consistent with the findings of Kullberg et 
a/., who showed that G-CSF helps non-neutropenic mice to 
fight challenge with candidiasis [12]. Mice treated with a single 
dose of G-CSF showed a significant reduction in mortality and 
in fungal growth from kidneys, spleen and liver. In contrast, 
administration of G-CSF to mice with profound and sustained 
neutropenia had no effect on the number of PMNs, the coume 
of infection or mortality. There were also no differences in the 
outgrowth of C. albicans in the same organs (Table 2).  
Human immunodeficiency virus (HIV)-infected patients 
possess defective PMN and M N C  function against both C. 
albicans and A. fumigatus [8,9,40]. G-CSF restored the reduced 
anti-Candida and anti-Aspergilus activity of PMNs from HIV- 
infected patients in M'tro. 
Another indication that the effects of G-CSF vary with 
different immunodeficiency states is derived from the study of 
Polak-Wyss. In that study, G-CSF gven to cyclopho- 
sphamide-treated mice was reported to offer protection &om 
subsequent development of aspergdosis and candidiasis 
[ 13,191. However, corticosteroid-treated mice were protected 
only when simultaneous G-CSF and antifungal chemotherapy 
with an azole was administered [19]. Immunocompetent mice 
were protected by G-CSF administration &om aspergdosis 
and candidiasis in a sigmficant degree. The above findings with 
corticosteroid-treated mice and aspergdlosis agree with those 
of Graybill et al. [20]. These authors, beginning 3 days before 
infection, administered either recombinant G-CSE or posa- 
conazole or both to corticosteroid-pretreated mice. G-CSF 
strongly antagonized the antihngal activity of posaconazole. 
These findings suggest that host ictors may contribute to the 
effects of cytolune therapy on IF1 in Merent  ways. 
DOES 6-CSF WORK BETTER AS PROPHYLAXIS OR TREAT- 
MENT OF IFI? 
Although it has not been clearly demonstrated whether G-CSF is 
more efficient as prophylaxis, early treatment or late treatment of 
IFI, some studies suggest that early administration of G-CSF is 
more effective than late adminiseation. In the rabbit model of 
invasive candidiasis, G-CSF treatment showed no effect in the 
case of penistent neutropenia and cand~diasis [17]. Nevertheless, 
Graybill et ai. [14] suggested that G-CSF in combination with 
fluconazole was beneficial in an acute murine candidiasis model, 
whether as prophylaxis or early treatment in both neutropenic 
and non-neutropenic mice. However, while the combined 
regimen prolonged the survival as prophylaxis, it had no effect on 
suMval and only reduced the kidney tissue counts significantly as 
treatment. In addition, Kullberg et al. [12] have demonstrated a 
maximal d e c t  of G-CSF on survival of mice with candidiasis 
when it was given 24 h before the infection. When treatment 
with G-CSF was begun after infection, no sigdicant improve- 
ment in survival was found. C h c a l  data on this issue do not exist. 
ARE THERE SPECIFIC FUNGAL INFECTIONS FOR WHICH G- 
CSF WORKS BETTER? 
The activity of G-CSF has not been compared against various 
IFI, including candidiasis and aspergosis. Recently, G-CSF 
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was administered to healthy volunteers and PMN-mehated 
antdimgal activity was evaluated against C. albicans, A. 
fumigafus and Rhiropus atrhizus. G-CSF signhcantly enhanced 
PMN-mediated killing of A. firmigatus and R. arrhirus conidia. 
In contrast, PMN-mediated killing of C. albicans was 
unaffected. Additionally, G-CSF increased the PMN oxidative 
bunt in response to extracts of above fungi ['I]. Subsequently, 
PMNs were taken &om G-CSF-treated healthy volunteers and 
their function was evaluated against C. albicans, A. fumigatus 
and Fusarium solani ex viva It was found that G-CSF did not 
significantly enhance PMN antifungal activity against hyphae 
of F. solani and A.fitmigatur but had enhancing effects against 
C. albicans pseudohyphae which predominate at sites of 
invasive tissue infection [41]. 
CONCLUSION: FUTURE DIRECTIONS 
Based on the studies presented here, administration of 
G-CSF appears to protect against IF1 by two means. It 
shortens the period of neutropenia during which patients are 
placed at high risk and it may enhance the functional activity 
of PMNs thus increasing the antifungal effectiveness of the 
PMNs that are present during the period of neutropenia. 
G-CSF has been suggested to be less suitable for use in 
patients with profound and prolonged neutropenia and IFI. 
However, in situations where either the patient is not 
profoundly neutropenic or PMNs are transfused from a 
healthy donor, G-CSF could greatly assist by enhancing the 
activity of these cells. Thus, prophylactic administration of 
G-CSF during the period of neutropenia or administration 
soon after the onset of the IF1 may enhance its beneficial 
effect. Further clinical studies should focus on the study of 
prophylaxis or early treatment of conditions that have been 
preclinically shown to be responsive to such therapy is an 
adjunct to antifungal agents. 
REFERENCES 
1. Dale DC. Potential role of colony-stimulating factors in the prevention and 
treatment of infectious diseases. Clin Infecr Dis 1994; 18 (Suppl. 2): S180- 
8. 
2. Roilides E, Uhlig K, Venzon D, Pizzo PA, Wakh 17. Neutrophil oxidative 
burst in response to blastoconidia and pseudohyphae of Candida albicans: 
Augmentation by granulocyte colony-stimulating factor and interferon-y. J 
Infat Dis 1992; 166: 668-73. 
3. Roilides E, Uhlig K, Venzon D. Pizzo PA, Walsh TJ. Enhancement of 
oxidative response and damage caused by human neutrophils to Aspergillus 
fiimigatirs hyphae by granulocyte colony-stimulating factor and gamma 
inteerferon. Infect lmmun 1993; 61: 1185-93. 
4. Yamamoto Y, Klein TW, Freidman H, Kimura S, Ya&aguchi H. 
Granulocyte-colony stimulating factor potentiates anti-Candida albicans 
growth inhibitory activity of polymorphonuclear cells. FEMS Immunol Med 
Mimobiol 1993; 7: 15-22. 
5. Roilides E, Holmes A, Blake C, Pizzo PA, Walsh TJ. Effects ofgranulocyte 
colony-stimulating factor and interferon-y on antifungal activity of human 
polymorphonuclear neutrophils against pseudohyphae of different medi- 
cally important Candida species.J Leirkoc Biol 1995; 57: 651-6. 
6. Gaviria JM, van Bunk JA, Dale DC, Root RK, Liles WC. Comparison of 
interferon-gamma, granulocyte colony-stimulating factor, and granulocyte- 
macrophage colony-stimulating factor for priming leukocyte-mediated 
hyphal damage of opportunistic fungal pathogens. J Infecl Dis 1999; 179: 
7. Liles WC, Huang JE, van Bunk JA, Bowden RA, Dale DC. Granulocyte 
colony-stimulating factor administered in vivo augments neutrophil- 
mediated activity against opportunistic fungal pathogens. J Infect Dis 1997; 
175: 1012-5. 
8. Vecchiarelli AC, Monari C, Baldeili F PI a/. Beneficial effect of recombinant 
human granulocyte colony-stimukting factor on fungicidal activity of 
polymorphonuclear leukocytes from patients with A1DS.J infert Dis 1995; 
171: 1448-54. 
9. Roilides E, Holmes A, Blake C, Pizzo PA, Walsh TJ Impairment of 
neutrophil fungicidal activity in HIV-infected children against Aspngillus 
jrmigattrs hyphae.J Znfect Dis 1993; 167: 905-1 1. 
10. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. Prevennon of 
comcosteroid-induced suppression of human polymorphonuclear leuko- 
cyte-induced damage of A s p q i l l ~ r s ~ m i g a t ~ r s  hyphae by granulocyte colony- 
stimulating factor and inreerferon-y. Intct lmmun 1993; 61: 4870-7. 
11. Roilides E, Dignani MC, Anaissie EJ, Rex JH. The role of immunor- 
econstitution in the management of refractoly opportunistic fungal 
infections. Med Mycol 1998; 3 6  12-25. 
12. Kuilherg BJ, van der Meer JW, Meis JF, Keuter M, C u d  JH, Netea MG. 
Recombinant murine granulocyte colony-stimulating factor protects 
against acute disseminated Candida albicdm infection in nomeutropenic 
mice.J Infci Dis 1998; 177: 175-81. 
13. Polak-Wyss A. Protective effect of human granulocyte colony-stimulating 
factor on Candida infections in normal and immunosuppressed mice. 
Mycoses 1991; 34: 109-18. 
14. Graybill JR, Bocanerga R ,  Luther M. Antifungal combination with G-CSF 
and fluconazole in experimental disseminated candidiasis. Eur J Clin 
Mimbiol lnfpct Dir 1995; 14: 700-3. 
15. Uchida K, Yamamoto Y, Klein TW, Friedman H, Yamaguchi H. 
Granulocyte-colony stimulating factor facilitates the restoration of resistance 
to opportunistic fungi in leukopenic mice.J Med Vet Mycol 1992; 3 0  293- 
300. 
16. Hamood M, Bluche PF, De Vroey C, Corazza F, Buzan W, Fondu P. 
Effects of rhG-CSF on neutropenic mice infected with C. albicam: 
acceleration of recovery from neutropenia and potentiation of anti-Candida 
resistance. Mycoses 1994; 37: 93-9. 
17. Arenberg D, Navarro E, Roilides E el a/. Effecu of granulocyte colony- 
stimulating factor in experimental hepatosplenic candidiasis in granulocy- 
topenic rabbits [Abstract no. FW]. In: Abstracts ofthe Annual Meeh'ng ofthe 
American Soriery of Microbiology. Washington, D C  American. Society for 
Microbiology, 1990. 
18. Kullberg BJ, Netea MG, Vonk AG, van der Meer JW. Modulation of 
neutrophil function in host defense against disseminated Candida albicans 
infection in mice. FEMS Immunol Med Minobiol 1999; 26: 299-307. 
19. Polak-Wyss A. Protective effect of human granulocyte colony-stimulating 
factor on Crptococms and Aspergillus infections in normal and immuno- 
suppressed mice. Mycoses 1991; 34: 205-15. 
20. Graybill JR, Bocanegra R, Najvar LK, Loebenberg D, Luther MF. 
Granulocyte colony-stimulating factor and azole antifungal therapy in 
murine aspergillosis: role of immune suppression. Andmimob Agents 
Chemother 1998; 42: 2467-73. 
21. Muranaka H, Suga M, Nakagawa K, Sat0 K. Gushima Y, Ando M. Effects 
1038-41. 
(%, 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 7 (Suppl. 2). 62-67 
Roilides and Farmaki Granulocyte colony-stimulating factor 67 
of granulocyte and granulocyte-macrophage colony-stimulating factors in a 
neutropenic murine model of mchosporonosis. lnfecf lmmrin 1997; 65: 
3422-9. 
22. Ozsahin H, van Planta M, Muller 1 et al. Successful treatment of invasive 
aspergillosis in chronic granulomatous disease by bone marrow transplanta- 
tion, granulocyte colony-stimulating factor-mobilized granulocytes, and 
liposomal amphotericin-B. Blood 1998; 92: 2719-24. 
23. Grauer ME, Bokemeyer C, Bautsch W ,  Freund M, Link H. Successful 
treatment of a Trichosporon beigelii septicemia in a granulocytopenic patient 
with amphotericin B and granulocyte colony-stimulating factor. Infection 
1994; 22: 283-6. 
24. Gonzalez CE, Couriel DR,  Walsh TJ. Successhl treatment of disseminated 
zygomycosis in a neutropenic patient with amphotericin B lipid complex 
and granulocyte colony-stimulating factor. Clin Infect Dis 1997; 24: 192-6. 
25. Hennequin C, Benkerrou M, Gaillard JL, Blanche S, Fraitag S. Role of 
granulocyte colony-stimulating factor in the management of infection with 
Frrsan'um oryspomm in a neutropenic child. Clin Infict Dis 1994; 18: 490-1. 
26. Fukushima T, Sumazaki R ,  Shibasaki M el al. Successful treatment of 
invasive thoracopulmonary mucormycisis in a patient with acute 
lymphoblastic leukemia. Cancer 1995; 7 6  895-9. 
27. Sahin B, Paydas S, Cosar E, Bicacki K, Hazar B. Role of granulocyte 
colony-stimulating factor in the treatment of mucormycosis. Eirr J Clin 
Microbiol Infect Dis 1996; 15: 8613-9. 
28. Dombusch HJ, Urban CE, Pinter H ef nl. Treatment of invasive pulmonary 
aspergillosis in severely neutropenic children with malignant disorders using 
liposomal amphotericin B, granulocyte colony-stimulating factor and 
surgery: repolr of 5 cases. Pediafr Hematof Onrol 1995; 12: 577-86. 
29. Erduran E, Yildiran A, Gedik Y. Multiple fungal brain abscesses in a child 
with acute myeloblastic leukemia. Pediatr Hemafol Oncol 1998; 15: 463-6. 
30. Aviles A, Guzman R, Garcia EL, Talavera A, Diaz-MaqueoJC. Resule of a 
randomized trial of granulocyte colony-stimulating factor in patients with 
infection and severe granulocytopenia. Anti-Cancer Agents 1996; 7: 392-7. 
31. Heil G, Hoelzer D, Sanz MA et 01. A randomized, double-blind, placebo- 
controlled, phase Ill study of Filgrastin in remission induction and 
consolidation therapy for adults with de novo acute myeloid leukemia. 
Blood 1997; 9 0  4710-8. 
32. Kullberg BJ, van de Woude K, Aoun M ef af. A double-blind, randomized, 
placebo-controlled phase 11 study of filgrastim (recombinant granulocyte 
colony-stimluating factor) in combination with tluconazole for ueatment of 
invasive candidiasis and candidemia in nonneutropenic patients (Abstract J- 
100). In: Program and Abstracts .f the 38th lnterscience Conference Antimioob 
Agents Chemother. San Diego CA. 1998. 
33. Vora S ,  Chauhan S, Brummer E, Stevens DA. Activity of voriconazole 
combined with neutrophils or monocytes against Aspergillus ftirn&atrrs: 
effects of granulocyte colony-stimulating factor and granulocyte-macro- 
phage colony-stimulating tzctor. Antimicrob Agenfs Chemother 1998; 42: 
2299-303. 
34. Vora S, Purimeda N, Brummer E, Stevens DA. Activity ofvoriconazole, a new 
triazole, combined with neutrophils or monocytes against Candida albicuns: 
Effect of granulocyte colony-stimulating factor and granulocyte-macrophage 
colony-stimulating factor. Antim'nob Afenfs Chemother 1998; 42: 907-10. 
35. Natarajan U, Randhawa N, Brummer E, Stevens DA. Effect of 
granulocyte-macrophage colony-stimulating factor on candidacidal activity 
of neutrophils, monocytes or monocyte-derived macrophages and synergy 
with 5uconazole. J Med Microbiol 1998 47: 359-63. 
36. Natarajan U, Brummer E, Stevens DA. Effect of granulocyte colony- 
stimulating factor on the candidacidal activity of polymorphonuclear 
neutrophils and their collaboration with fluconazole. Antimicrob Agents 
Chemother 1997; 41: 1575-8. 
37. Nemunaitis J, Cox J. Meyer W el ol. Comparison of neutrophil and 
monocyte function by microbicidal cell-kill assay in patients with cancer 
receiving granulocyte colony-stimulating factor, granulocyte-macrophage 
colony-stimulating factor, or no cytokine after cytotoxic chemotherapy. 
Am J Clin Onrol 1998; 21: 308-12. 
38. Peters BG, Adkins DR,  Harrison B et al. Antifungal effects of yeast-derived 
rhu-GM-CSF in patients receiving high-dose chemotherapy given with or 
without autologous stem cell transplantation: a retrospective analysis. Bone 
Marrow Transplant 1996; 18 93-102. 
39. Dignani MC, Freireich EJ, Andenson BS et al. Treatment of neutropenia- 
related fungal infections with granulocyte colony-stimulating factor-elicited 
white blood cell transfusions: a pilot study. Lenkemia 1997; 11: 1621-30. 
40. Roilides E, Holmes A, Blake G, Pizzo PA, Walsh TJ. Defective antifungal 
activity of monocyte-derived macrophages from HIV-infected children 
against Aspergiflusftimigatus. J In@ Dis 1993; 168 1562-5. 
41. Gaviria JM, van Bunk JA, Dale DC, Root RK, Liles WC. Modulation of 
neutrophil-mediated activity against the pseudohyphal form of Candida 
albicans by granulocyte colony-stimulating factor (G-CSF) administered in 
vivo. J Infect Dis 1999; 179: 1301-4. 
Q 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CM/, 7 (Suppl. 2), 62-67 
